OTE May Edit List
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued
A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.